CA3131299A1 - Anti-cd6 antibody compositions and methods for treating lupus - Google Patents
Anti-cd6 antibody compositions and methods for treating lupus Download PDFInfo
- Publication number
- CA3131299A1 CA3131299A1 CA3131299A CA3131299A CA3131299A1 CA 3131299 A1 CA3131299 A1 CA 3131299A1 CA 3131299 A CA3131299 A CA 3131299A CA 3131299 A CA3131299 A CA 3131299A CA 3131299 A1 CA3131299 A1 CA 3131299A1
- Authority
- CA
- Canada
- Prior art keywords
- alcam
- subject
- soluble
- sample
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810628P | 2019-02-26 | 2019-02-26 | |
| US62/810,628 | 2019-02-26 | ||
| US201962933294P | 2019-11-08 | 2019-11-08 | |
| US62/933,294 | 2019-11-08 | ||
| PCT/US2020/019990 WO2020176682A1 (en) | 2019-02-26 | 2020-02-26 | Anti-cd6 antibody compositions and methods for treating lupus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3131299A1 true CA3131299A1 (en) | 2020-09-03 |
Family
ID=70009403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3131299A Pending CA3131299A1 (en) | 2019-02-26 | 2020-02-26 | Anti-cd6 antibody compositions and methods for treating lupus |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220143140A1 (enExample) |
| EP (1) | EP3930751A1 (enExample) |
| JP (1) | JP2022521973A (enExample) |
| CN (1) | CN113490511B (enExample) |
| AU (1) | AU2020229830A1 (enExample) |
| BR (1) | BR112021016967A2 (enExample) |
| CA (1) | CA3131299A1 (enExample) |
| MX (1) | MX2021010283A (enExample) |
| PH (1) | PH12021551994A1 (enExample) |
| SG (1) | SG11202109118XA (enExample) |
| WO (1) | WO2020176682A1 (enExample) |
| ZA (1) | ZA202107077B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| JP2023552762A (ja) * | 2020-12-04 | 2023-12-19 | エクイリウム，インコーポレイテッド | Ｃｄ６ｈｉｇｈ細胞を選択的に標的化してｔｅｆｆ細胞の活性を低下する方法 |
| EP4533094A4 (en) * | 2022-05-25 | 2026-05-06 | Univ Houston System | Methods and systems for risk stratification and management of bladder cancer |
| TWI869873B (zh) * | 2023-06-05 | 2025-01-11 | 中國醫藥大學 | 一種檢測一個體罹患單純復發性風濕病的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998172A (en) * | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CU22584A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| WO1998043089A1 (en) * | 1997-03-03 | 1998-10-01 | Bristol-Myers Squibb Company | Monoclonal antibodies to human cd6 |
| KR101482959B1 (ko) | 2006-12-26 | 2015-01-15 | 센트로 데 인뮤놀러지아 모레큘러 | Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물 |
| WO2009113083A1 (en) * | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| JP5900489B2 (ja) * | 2011-03-25 | 2016-04-06 | コニカミノルタ株式会社 | 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法 |
| BR112013033988B1 (pt) * | 2011-07-01 | 2021-10-19 | Beckman Coulter, Inc. | Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras |
| AU2013229786B2 (en) * | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| WO2015107501A1 (en) * | 2014-01-20 | 2015-07-23 | Ghiggeri Gian Marco | In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis |
| EP3439658B1 (en) * | 2016-04-04 | 2021-11-24 | ChemoCentryx, Inc. | Soluble c5ar antagonists |
| WO2017214452A1 (en) * | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| ES2991182T3 (es) * | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
-
2020
- 2020-02-26 BR BR112021016967A patent/BR112021016967A2/pt unknown
- 2020-02-26 SG SG11202109118XA patent/SG11202109118XA/en unknown
- 2020-02-26 CN CN202080016831.1A patent/CN113490511B/zh active Active
- 2020-02-26 JP JP2021549772A patent/JP2022521973A/ja not_active Ceased
- 2020-02-26 US US17/434,247 patent/US20220143140A1/en not_active Abandoned
- 2020-02-26 CA CA3131299A patent/CA3131299A1/en active Pending
- 2020-02-26 WO PCT/US2020/019990 patent/WO2020176682A1/en not_active Ceased
- 2020-02-26 EP EP20714769.5A patent/EP3930751A1/en active Pending
- 2020-02-26 AU AU2020229830A patent/AU2020229830A1/en active Pending
- 2020-02-26 PH PH1/2021/551994A patent/PH12021551994A1/en unknown
- 2020-02-26 MX MX2021010283A patent/MX2021010283A/es unknown
-
2021
- 2021-09-22 ZA ZA2021/07077A patent/ZA202107077B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109118XA (en) | 2021-09-29 |
| CN113490511B (zh) | 2024-07-09 |
| PH12021551994A1 (en) | 2022-08-15 |
| ZA202107077B (en) | 2023-07-26 |
| JP2022521973A (ja) | 2022-04-13 |
| CN113490511A (zh) | 2021-10-08 |
| BR112021016967A2 (pt) | 2021-11-23 |
| MX2021010283A (es) | 2021-09-30 |
| EP3930751A1 (en) | 2022-01-05 |
| AU2020229830A1 (en) | 2021-09-16 |
| WO2020176682A1 (en) | 2020-09-03 |
| US20220143140A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110214154B (zh) | 抗cd47抗体及其用途 | |
| US20220143140A1 (en) | Anti-cd6 antibody compositions and methods for treating lupus | |
| US10202454B2 (en) | Anti-PD-L1 monoclonal antibodies and fragments thereof | |
| KR101361905B1 (ko) | 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도 | |
| JP7142200B2 (ja) | ＭＡｄＣＡＭアンタゴニストの投与レジメン | |
| CN111630068A (zh) | 抗cd47抗体及其用途 | |
| KR102223464B1 (ko) | Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법 | |
| CN107318267B (zh) | 用于治疗补体相关的病症的组合物和方法 | |
| CA3000725A1 (en) | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof | |
| MX2015003932A (es) | Metodos para diagnosticar y tratar la enfermedad inflamatoria intestinal. | |
| US12258409B2 (en) | Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies | |
| CN112638945A (zh) | 人白介素18受体α和β的人抗体 | |
| JP2025518110A (ja) | 腎臓疾患又は障害を治療する方法 | |
| CA3257247A1 (en) | METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | |
| EP3062817B1 (en) | Il-3 blockade in systemic lupus erythematosus and multiple sclerosis | |
| HK40052994A (en) | Anti-cd6 antibody compositions and methods for treating lupus | |
| WO2019199896A1 (en) | Agonist antibodies against human cd137 in cancer that express mhc i | |
| WO2019200357A1 (en) | Biomarker for cd47 targeting therapeutics and uses therefor | |
| HK40052994B (zh) | 用於治疗狼疮的抗cd6抗体组合物和方法 | |
| WO2023115029A2 (en) | Antibody-based depletion of il1r2-positive cells | |
| BR112020016400A2 (pt) | Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias | |
| HK40043719A (en) | Human antibodies to human interleukin 18 receptor alpha and beta | |
| HK1239758A1 (en) | Compositions and method for treating compliment-associated conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231222 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250612 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251014 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260409 |